SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014502
Filing Date
2023-08-10
Accepted
2023-08-10 16:10:55
Documents
83
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ymab-20230630x10q.htm   iXBRL 10-Q 2233726
2 EX-31.1 ymab-20230630xex31d1.htm EX-31.1 15649
3 EX-31.2 ymab-20230630xex31d2.htm EX-31.2 15557
4 EX-32.1 ymab-20230630xex32d1.htm EX-32.1 7910
5 EX-32.2 ymab-20230630xex32d2.htm EX-32.2 7828
  Complete submission text file 0001558370-23-014502.txt   8309660

Data Files

Seq Description Document Type Size
6 EX-101.SCH ymab-20230630.xsd EX-101.SCH 63381
7 EX-101.CAL ymab-20230630_cal.xml EX-101.CAL 45318
8 EX-101.DEF ymab-20230630_def.xml EX-101.DEF 245578
9 EX-101.LAB ymab-20230630_lab.xml EX-101.LAB 486673
10 EX-101.PRE ymab-20230630_pre.xml EX-101.PRE 407223
77 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20230630x10q_htm.xml XML 1316225
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38650 | Film No.: 231159458
SIC: 2834 Pharmaceutical Preparations